During 2018 Q4 the big money sentiment decreased to 0.94. That’s change of 0.81, from 2018Q3’s 1.75. 61 investors sold all, 89 reduced holdings as Nektar Therapeutics ratio turned negative. 101 increased holdings while 40 funds acquired holdings. Funds hold 160.47 million shares thus 4.08% more from 2018Q3’s 154.18 million shares.
Assetmark owns 368 shs or 0% of their US capital. State Of Wisconsin Invest Board invested in 238,612 shs or 0.03% of the stock. Utah Retirement reported 0.02% of its capital in Nektar Therapeutics (NASDAQ:NKTR). Mackay Shields Ltd Liability Company owns 26,337 shs. Profund Advsrs Ltd Com reported 48,895 shs stake. Utd Automobile Association stated it has 63,696 shs. State Of Alaska Department Of Revenue holds 48,377 shs. Van Eck accumulated 216,881 shs. Amer Grp invested in 0.01% or 71,470 shs. Rhumbline Advisers has invested 0.03% of its capital in Nektar Therapeutics (NASDAQ:NKTR). Moreover, Birchview Capital Lp has 0.3% invested in Nektar Therapeutics (NASDAQ:NKTR). State Treasurer State Of Michigan owns 49,600 shs or 0.01% of their US capital. Fil Ltd holds 10 shs or 0% of its capital. Swiss Commercial Bank holds 0.02% of its capital in Nektar Therapeutics (NASDAQ:NKTR) for 561,000 shs. Gam Hldgs Ag accumulated 42,202 shs.

Nektar Therapeutics registered $6.10 million net activity with 0 insider buys and 11 insider sales since September 19, 2018. On Thursday, September 20 $512,820 worth of stock was sold by Lingnau Lutz. Thomsen Jillian B. sold $153,612 worth of stock. Labrucherie Gil M also sold $249,199 worth of Nektar Therapeutics (NASDAQ:NKTR) on Friday, November 16. 6,750 shs valued at $383,130 were sold by Ajer Jeffrey Robert on Thursday, September 20. 15,326 Nektar Therapeutics (NASDAQ:NKTR) shs with value of $586,220 were sold by ROBIN HOWARD W. On Wednesday, September 19 CHESS ROBERT sold $255,645 worth of Nektar Therapeutics (NASDAQ:NKTR).

Nektar Therapeutics (NASDAQ:NKTR) rose to $37.66. On Mar, 13 it was posted by Barchart.com. The company has $6.56B market cap. The company’s valuation will be $458.99 million more at $40.30 target.

Investors wait Nektar Therapeutics (NASDAQ:NKTR)’s quarterly earnings on May, 9., as reported by Faxor. Analysts forecast $-0.62 earnings per share, which is $0.02 down or 3.33 % from 2018’s $-0.6 earnings per share. After $-0.57 EPS report previous quarter, Wall Street now sees 8.77 % negative EPS growth of Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Total analysts of 7 have positions in Nektar Therapeutics (NASDAQ:NKTR) as follows: 6 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 86%. Since November 8, 2018 according to StockzIntelligence Inc Nektar Therapeutics has 10 analyst reports. On Friday, March 1 the stock has “Buy” rating by Piper Jaffray. On Thursday, November 8 the firm has “Buy” rating by Jefferies given. On Tuesday, November 13 the stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given by Canaccord Genuity. On Tuesday, February 19 the rating was maintained by H.C. Wainwright with “Hold”. The stock rating was maintained by Mizuho with “Buy” on Tuesday, February 19. On Monday, March 4 the stock has “Hold” rating by H.C. Wainwright. On Friday, March 1 the stock has “Buy” rating by Mizuho.

For more Nektar Therapeutics (NASDAQ:NKTR) news released briefly go to: Benzinga.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Benzinga.com. The titles are as follows: “44 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” released on February 12, 2019, “Nektar -5.9% as it reports urothelial cancer study – Seeking Alpha” on February 11, 2019, “What’s in the Cards for Nektar (NKTR) This Earnings Season? – Nasdaq” with a publish date: February 25, 2019, “Wednesday Sector Laggards: Healthcare, Energy – Nasdaq” and the last “Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal – Benzinga” with publication date: February 15, 2019.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States.The firm is worth $6.56 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain.9.96 is the P/E ratio. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.